Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Market Reports
NEW
 Top 50 Non-Healthcare Market Reports
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Minimal Residual Disease Testing Global Market Report 2025
Request Sample Buy Now
Global Minimal Residual Disease Testing Market Report 2025

Report Price : $4490.00

Pages : 200

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Minimal Residual Disease Testing Global Market Report 2025

By Test Type (DNA - Based Test, RNA- Based Test, Immunological Test), By Technology (Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies ), By Application (Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application), By End User (Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic and Research Institutes, Other End Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Minimal Residual Disease Testing Market Overview

• Minimal Residual Disease Testing market size has reached to $1.59 billion in 2024

• Expected to grow to $2.91 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%

• Growth Driver: Rising Cancer Prevalence Fueling Growth In Minimal Residual Disease Testing Market

• Market Trend: Innovative Product Developments Transforming The Minimal Residual Disease Testing Market

• North America was the largest region in 2024.

What Is Covered Under Minimal Residual Disease Testing Market?

Minimal residual disease testing refers to a very sensitive test to detect cancer cells in the patient's body that may remain after treatment. It is used to monitor the effectiveness of cancer treatment and inform future treatment strategies.

The main test types of minimal residual disease testing are DNA- based tests, RNA- based tests, and immunological tests. DNA (deoxyribonucleic acid)-based testing (also known as genetic testing) is a type of medical examination that can spot changes to your chromosomes, genes, or proteins. The various technologies include flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others, are used in various applications such as hematological malignancies, leukemia, lymphoma, solid tumors, and others. These are used by hospitals and specialty clinics, diagnostic laboratories, academic and research institutes, and others.

Minimal Residual Disease Testing Global Market Report 2025 Market Size and growth rate 2025 to 2029: Graph

What Is The Minimal Residual Disease Testing Market Size 2025 And Growth Rate?

The minimal residual disease testing market size has grown rapidly in recent years. It will grow from $1.59 billion in 2024 to $1.8 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to advancements in cancer research, treatment monitoring needs, clinical evidence, regulatory support, patient outcome improvement.

What Is The Minimal Residual Disease Testing Market Growth Forecast?

The minimal residual disease testing market size is expected to see rapid growth in the next few years. It will grow to $2.91 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to increasing cancer incidence, therapeutic advancements, precision medicine trends, shift toward early detection, healthcare system integration. Major trends in the forecast period include integration of liquid biopsy approaches, focus on early detection of relapse, expansion of MRD testing in clinical trials, increasing adoption in pediatric oncology, collaborations for research and development.

The forecast of 12.8% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. cancer diagnostics by inflating prices of next-generation sequencing-based measurable residual disease panels and digital polymerase chain reaction systems developed in South Korea and Belgium, resulting in delayed relapse detection and higher precision oncology testing costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

What’s The Trade War Impact On Pharmaceuticals Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

How Is The Minimal Residual Disease Testing Market Segmented?

1) By Test Type: DNA- Based Test, RNA- Based Test, Immunological Test

2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies

3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application

4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users

Subsegments:

1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests, Next-Generation Sequencing (NGS), Digital PCR

2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR), RNA Sequencing, Quantitative PCR (qPCR)

3) By Immunological Test: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry

What Is Driving The Minimal Residual Disease Testing Market? Rising Cancer Prevalence Fueling Growth In Minimal Residual Disease Testing Market

The increasing prevalence of cancer is expected to propel the growth of the minimal residual disease testing market going forward. Cancer refers to a condition when a few of the body's cells grow out of control and spread to other bodily regions. Cancer stages are primarily detected through minimal residual disease testing, which is a very sensitive method to detect cancer cells in the human body. It helps cancer patients prevent the disease at an early stage, boosting the minimal residual disease testing market. For instance, in 2022, according to the reports shared by the American Cancer Society Inc., a US-based nonprofit organization, approximately 1.9 million fresh instances of cancer are projected to be diagnosed, leading to an estimated 609,360 cancer-related fatalities in the United States in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the minimal residual disease testing industry.

What Is Driving The Minimal Residual Disease Testing Market? Rising Demand For Personalized Medicine Drives Growth In The Minimal Residual Disease Testing Market

Rising demand for personalized medicine is expected to propel the growth of the minimal residual disease testing market going forward. Personalized medicine customizes healthcare interventions based on individual characteristics such as genetics, lifestyle, and environment to optimize treatment. Personalized medicine tailors’ treatments based on a patient's unique genetic profile, optimizing minimal residual disease testing to precisely monitor residual cancer cells post-treatment, aiding in more targeted therapies for better outcomes. For instance, in 2022, according to the Personalized Medicine Coalition, a US-based professional membership organization, the Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) approved 37 new molecular entities (NMEs) in 2022. Out of the 35 therapeutic NMEs, approximately 34%, which amounts to 12 of them, are classified as personalized medicines by the Personalized Medicine Coalition (PMC). Therefore, the rising demand for personalized medicine is driving the growth of the minimal residual disease testing industry.

Who Are The Major Players In The Global Minimal Residual Disease Testing Market?

Major companies operating in the minimal residual disease testing market include Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton, Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Janssen Diagnostics LLC, Luminex Corporation, Menarini Silicon Biosystems S.p.A.

What Are The Key Trends Of The Global Minimal Residual Disease Testing Market? Innovative Product Developments Transforming The Minimal Residual Disease Testing Market

Product innovations are a key trend gaining popularity in the minimal residual disease testing market. Major companies operating in the minimal residual disease testing market are innovating new products to sustain their position in the market. For instance, in 2022, Twist Bioscience, a US-based synthetic biology and genomics company, launched Twist MRD Panel to advance research and development in minimal residual disease (MRD) detection in cancer screening. Twist MRD Panel is a customizable panel of genes that can be used to detect very low levels of residual cancer cells in a patient's blood. The Twist MRD Panel is designed to be highly flexible and customizable that can be integrated into a typical next-generation sequencing (NGS) workflow that can find minimum residual disease (MRD) in just five days.

What Are The Key Trends Of The Global Minimal Residual Disease Testing Market? Advancements In Cancer Research Testing Enhance The Minimal Residual Disease Testing Market

Major companies in the minimal residual disease testing market are launching cancer research testing solutions to enhance detection sensitivity, improve treatment monitoring, and advance precision medicine approaches for better patient outcomes. The IDT Archer FUSIONPlex Core Solid Tumor Panel refers to a targeted next-generation sequencing assay used for detecting gene fusions and mutations in solid tumors, aiding in precision oncology and treatment decision-making. For instance, in April 2023, Integrated DNA Technologies (IDT), a US-based provider of genomic solutions, launched the IDT Archer FUSIONPlex Core Solid Tumor Panel, enhanced cancer research testing solution, now offering expanded and optimized coverage for single nucleotide variants (SNVs) and indels. This RNA-based sequencing assay simplifies fusion detection and variant calling in solid tumors, utilizing a single sample input and offering researchers a scalable, user-friendly solution that saves time, resources, and costs.

Need data on a specific region in this market?
Request Customisation

Minimal Residual Disease Testing Market Merger And Acquisition: Illumina Inc. Complete Acquisition Of Grail To Expand Cancer Detection Capabilities

In April 2023, Quest Diagnostics, a US-based clinical laboratory, acquired Haystack Oncology. With this acquisition Quest aims to improve personalized cancer care through Haystack's liquid biopsy technology. This approach detects residual or recurring cancer by identifying circulating tumor DNA (ctDNA) in the bloodstream. Haystack Oncology Inc is aUS-based biotechnology company.

Regional Analysis For The Global Minimal Residual Disease Testing Market

North America was the largest region in the minimal residual disease testing market in 2024. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Minimal Residual Disease Testing Market?

The minimal residual disease testing market includes revenues earned by entities by providing services such as peripheral blood cell testing, sequencing testing, high-throughput sequencing testing, and methylation sequencing testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Minimal Residual Disease Testing Industry?

The minimal residual disease testing market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the minimal residual disease testing industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Minimal Residual Disease Testing Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $1.8 billion
Revenue Forecast In 2034 $2.91 billion
Growth Rate CAGR of 12.8% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Test Type: DNA - Based Test, RNA- Based Test, Immunological Test
2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application
4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users Subsegments: 1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests, Next-Generation Sequencing (NGS), Digital PCR
2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR), RNA Sequencing, Quantitative PCR (qPCR)
3) By Immunological Test: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton, Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Janssen Diagnostics LLC, Luminex Corporation, Menarini Silicon Biosystems S.p.A.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Minimal Residual Disease Testing Market Characteristics

3. Minimal Residual Disease Testing Market Trends And Strategies

4. Minimal Residual Disease Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Minimal Residual Disease Testing Growth Analysis And Strategic Analysis Framework

5.1. Global Minimal Residual Disease Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Minimal Residual Disease Testing Market Growth Rate Analysis

5.4. Global Minimal Residual Disease Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Minimal Residual Disease Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Minimal Residual Disease Testing Total Addressable Market (TAM)

6. Minimal Residual Disease Testing Market Segmentation

6.1. Global Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

DNA - Based Test

RNA- Based Test

Immunological Test

6.2. Global Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Flow Cytometry

Polymerase Chain Reaction (PCR)

Next-Generation Sequencing (NGS)

Other Technologies

6.3. Global Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hematological Malignancies

Leukemia

Lymphoma

Solid Tumors

Other Application

6.4. Global Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals And Specialty Clinics

Diagnostic Laboratories

Academic and Research Institutes

Other End Users

6.5. Global Minimal Residual Disease Testing Market, Sub-Segmentation Of DNA-Based Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Polymerase Chain Reaction (PCR) Tests

Next-Generation Sequencing (NGS)

Digital PCR

6.6. Global Minimal Residual Disease Testing Market, Sub-Segmentation Of RNA-Based Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Reverse Transcription PCR (RT-PCR)

RNA Sequencing

Quantitative PCR (qPCR)

6.7. Global Minimal Residual Disease Testing Market, Sub-Segmentation Of Immunological Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Flow Cytometry

Enzyme-Linked Immunosorbent Assay (ELISA)

Immunohistochemistry

7. Minimal Residual Disease Testing Market Regional And Country Analysis

7.1. Global Minimal Residual Disease Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Minimal Residual Disease Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Minimal Residual Disease Testing Market

8.1. Asia-Pacific Minimal Residual Disease Testing Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Minimal Residual Disease Testing Market

9.1. China Minimal Residual Disease Testing Market Overview

9.2. China Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Minimal Residual Disease Testing Market

10.1. India Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Minimal Residual Disease Testing Market

11.1. Japan Minimal Residual Disease Testing Market Overview

11.2. Japan Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Minimal Residual Disease Testing Market

12.1. Australia Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Minimal Residual Disease Testing Market

13.1. Indonesia Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Minimal Residual Disease Testing Market

14.1. South Korea Minimal Residual Disease Testing Market Overview

14.2. South Korea Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Minimal Residual Disease Testing Market

15.1. Western Europe Minimal Residual Disease Testing Market Overview

15.2. Western Europe Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Minimal Residual Disease Testing Market

16.1. UK Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Minimal Residual Disease Testing Market

17.1. Germany Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Minimal Residual Disease Testing Market

18.1. France Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Minimal Residual Disease Testing Market

19.1. Italy Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Minimal Residual Disease Testing Market

20.1. Spain Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Minimal Residual Disease Testing Market

21.1. Eastern Europe Minimal Residual Disease Testing Market Overview

21.2. Eastern Europe Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Minimal Residual Disease Testing Market

22.1. Russia Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Minimal Residual Disease Testing Market

23.1. North America Minimal Residual Disease Testing Market Overview

23.2. North America Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Minimal Residual Disease Testing Market

24.1. USA Minimal Residual Disease Testing Market Overview

24.2. USA Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Minimal Residual Disease Testing Market

25.1. Canada Minimal Residual Disease Testing Market Overview

25.2. Canada Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Minimal Residual Disease Testing Market

26.1. South America Minimal Residual Disease Testing Market Overview

26.2. South America Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Minimal Residual Disease Testing Market

27.1. Brazil Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Minimal Residual Disease Testing Market

28.1. Middle East Minimal Residual Disease Testing Market Overview

28.2. Middle East Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Minimal Residual Disease Testing Market

29.1. Africa Minimal Residual Disease Testing Market Overview

29.2. Africa Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Minimal Residual Disease Testing Market Competitive Landscape And Company Profiles

30.1. Minimal Residual Disease Testing Market Competitive Landscape

30.2. Minimal Residual Disease Testing Market Company Profiles

30.2.1. Natera Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Guardant Health Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Laboratory Corporation of America Holdings Overview, Products and Services, Strategy and Financial Analysis

30.2.4. QIAGEN NV Overview, Products and Services, Strategy and Financial Analysis

30.2.5. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Minimal Residual Disease Testing Market Other Major And Innovative Companies

31.1. Bio-Techne Corporation

31.2. Bio-Rad Laboratories Inc.

31.3. Sysmex Corporation

31.4. Exact Sciences Corporation

31.5. GRAIL LLC

31.6. Veracyte Inc.

31.7. Cergentis B.V

31.8. Mdxhealth SA

31.9. NeoGenomics Laboratories Inc.

31.10. Adaptive Biotechnologies

31.11. OPKO Health Inc.

31.12. Thermo Fisher Scientific Inc.

31.13. Siemens Healthineers AG

31.14. PerkinElmer Inc.

31.15. Agilent Technologies Inc.

32. Global Minimal Residual Disease Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Minimal Residual Disease Testing Market

34. Recent Developments In The Minimal Residual Disease Testing Market

35. Minimal Residual Disease Testing Market High Potential Countries, Segments and Strategies

35.1 Minimal Residual Disease Testing Market In 2029 - Countries Offering Most New Opportunities

35.2 Minimal Residual Disease Testing Market In 2029 - Segments Offering Most New Opportunities

35.3 Minimal Residual Disease Testing Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Minimal Residual Disease Testing Market, Sub-Segmentation Of DNA-Based Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Minimal Residual Disease Testing Market, Sub-Segmentation Of RNA-Based Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Minimal Residual Disease Testing Market, Sub-Segmentation Of Immunological Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Minimal Residual Disease Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Minimal Residual Disease Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Natera Inc. Financial Performance
  • Table 79: Guardant Health Inc. Financial Performance
  • Table 80: Laboratory Corporation of America Holdings Financial Performance
  • Table 81: QIAGEN NV Financial Performance
  • Table 82: F. Hoffmann-La Roche Ltd. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Minimal Residual Disease Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Minimal Residual Disease Testing Market, Sub-Segmentation Of DNA-Based Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Minimal Residual Disease Testing Market, Sub-Segmentation Of RNA-Based Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Minimal Residual Disease Testing Market, Sub-Segmentation Of Immunological Test, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Minimal Residual Disease Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Minimal Residual Disease Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Minimal Residual Disease Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Minimal Residual Disease Testing Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Minimal Residual Disease Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Natera Inc. Financial Performance
  • Figure 79: Guardant Health Inc. Financial Performance
  • Figure 80: Laboratory Corporation of America Holdings Financial Performance
  • Figure 81: QIAGEN NV Financial Performance
  • Figure 82: F. Hoffmann-La Roche Ltd. Financial Performance

Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Read More About Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Read More About Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Read More About Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

Read More About Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Soft Drinks Global Market Report 2025 – By Product (Carbonated Soft Drinks, Juices And juice concentrates, Bottled Water, Ready-To-Drink (RTD) Tea And Coffee, Other Products), By Flavors (Cola, Citrus, Other Flavors), By...

View Report

Merkel Cell Carcinoma Treatment Global Market Report 2025 – By Diagnosis (Physical Examination, Sentinel Node Biopsy, Imaging Test), By Therapy (Surgical Excision, Micrographic Surgery, Radiation, Chemotherapy, Other The...

View Report

Aircraft Sensors Global Market Report 2025 – By Sensor Type (Temperature, Pressure, Position, Flow, Torque, Radar, Accelerometer, Proximity), By Aircraft Type (Narrow-Body Aircraft, Wide-Body Aircraft, Very Large Aircraf...

View Report

Allogeneic T Cell Therapies Global Market Report 2025 – By Product Type (Chimeric Antigen Receptor (CAR) T Cell Therapies, T Cell Receptor (TCR) Therapies, Other Product Types), By Antigen Type (CD 19, CD 20, Egfrvlll, G...

View Report

Sulfur Global Market Report 2025 – By Type (Fertilizers, Chemical Processing, Sulfur-Metal Manufacturing, Petroleum Refining, and Other Types- Sulfur), By Mining Type (Underground Mining, Surface Mining) – Impact Of Tari...

View Report

Halal Cosmetics Global Market Report 2025 – By Type (Skin Care, Hair Care, Makeup, Others), By Distribution Channel (Offline, Online), By End User (Men, Women, Unisex) – Impact of Tariff and Trade War on Market Size, Gro...

View Report

Organic Pigments Global Market Report 2025 – By Type (Azo Pigments, Pthalocyanine Pigments, High Performance Pigments (HPPs), Alizarin, Arylide, Other Types), By Source (Synthetic, Natural), By End-Use (Textile, Paints A...

View Report

Addictions Therapeutics Global Market Report 2025 – By Drug Type (Buprenorphine, Naltrexone, Bupropion, Disulfiram, Nicotine Replacement Products, Varenicline, Other Drugs), By Treatment Type (Opioid Addiction Treatment,...

View Report

Frequently Asked Questions

Minimal residual disease testing refers to a very sensitive test to detect cancer cells in the patient's body that may remain after treatment. It is used to monitor the effectiveness of cancer treatment and inform future treatment strategies. For further insights on this market, request a sample here

The market major growth driver - Rising Cancer Prevalence Fueling Growth In Minimal Residual Disease Testing Market. For further insights on this market, request a sample here

The minimal residual disease testing market size has grown rapidly in recent years. It will grow from $1.59 billion in 2024 to $1.8 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to advancements in cancer research, treatment monitoring needs, clinical evidence, regulatory support, patient outcome improvement. The minimal residual disease testing market size is expected to see rapid growth in the next few years. It will grow to " $2.91 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to increasing cancer incidence, therapeutic advancements, precision medicine trends, shift toward early detection, healthcare system integration. Major trends in the forecast period include integration of liquid biopsy approaches, focus on early detection of relapse, expansion of MRD testing in clinical trials, increasing adoption in pediatric oncology, collaborations for research and development. For further insights on this market, request a sample here

The minimal residual disease testing market covered in this report is segmented –
1) By Test Type: DNA - Based Test, RNA- Based Test, Immunological Test
2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application
4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users Subsegments:
1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests, Next-Generation Sequencing (NGS), Digital PCR
2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR), RNA Sequencing, Quantitative PCR (qPCR)
3) By Immunological Test: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry For further insights on this market, request a sample here

North America was the largest region in the minimal residual disease testing market in 2024. The regions covered in the minimal residual disease testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on this market, request a sample here.

Major companies operating in the minimal residual disease testing market include Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, OPKO Health Inc., Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton, Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Janssen Diagnostics LLC, Luminex Corporation, Menarini Silicon Biosystems S.p.A. . For further insights on this market, request a sample here.

Major trends in this market include Innovative Product Developments Transforming The Minimal Residual Disease Testing Market. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Minimal Residual Disease Testing Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top WhatsApp icon